Korean J Nephrol.  2006 Jan;25(1):135-140.

Two Cases of Heparin-Induced Thrombocytopenia in Hemodialysis Patients

• Choi HJ
• Lee DH
• Youn YD
• Kim SH
• Rhee JA
• Chang SH
• Suh JS

Abstract

Heparin, a widely used anticoagulant, is currently the anticoagulant of choice in long-term hemodialysis (HD). Heparin-induced thrombocytopenia (HIT) is one of the most serious side effects of heparin which can cause arterial or venous thromboembolism associated with substantial morbidity and mortality. We experienced two patients who had thrombocytopenia and vascular access occlusion during the induction period of HD with the use of unfractionated heparin. Thrombocytopenia was improved after discontinuation of heparin. HIT was confirmed with anti-heparin/platelet factor 4 antibody test. HD was conducted and arteriovenous fistula was created successfully after switch of heparin to argatroban (Novastan(R)) or nafamostat mesilate (Futhan(R)). Nephrologist should rule out HIT first when thrombocytopenia and thromboembolic complications occur after use of heparin, especially during the induction period of HD. For suspicious patients, immediate cessation of heparin and switch to alternative anticoagulant is very important to avoid serious complications.

Keyword

Heparin-induced thrombocytopenia; Hemodialysis; Anticoagulant

MeSH Terms

Arteriovenous Fistula
Heparin
Humans
Mesylates
Mortality
Renal Dialysis*
Thrombocytopenia*
Venous Thromboembolism
Heparin
Mesylates